Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Non Operating Income (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Non Operating Income for 10 consecutive years, with -$175000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 418.18% to -$175000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$213000.0 through Dec 2025, down 260.15% year-over-year, with the annual reading at $94000.0 for FY2024, N/A changed from the prior year.
  • Other Non Operating Income for Q4 2025 was -$175000.0 at Akebia Therapeutics, down from -$10000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $1.3 million in Q2 2021, with the low at -$906000.0 in Q3 2022.
  • Average Other Non Operating Income over 5 years is $132333.3, with a median of -$10000.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income surged 604.35% in 2022, then plummeted 418.18% in 2025.
  • Over 5 years, Other Non Operating Income stood at $1.3 million in 2021, then plummeted by 171.62% to -$906000.0 in 2022, then skyrocketed by 74.72% to -$229000.0 in 2023, then skyrocketed by 124.02% to $55000.0 in 2024, then tumbled by 418.18% to -$175000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$175000.0, -$10000.0, and -$28000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.